scholarly journals The effect of alpha lipoic acid in the treatment of multiple sclerosis induced neuropathic pain: A case report

2018 ◽  
Author(s):  
Fazıl Kulaklı
Keyword(s):  
Multiple Sclerosis ◽  
Neuropathic Pain ◽  
Case Report ◽  
Lipoic Acid ◽  
Alpha Lipoic Acid

scholarly journals Alpha lipoic acid attenuated neuropathic pain induced by chronic constriction Injury of sciatic nerve in rats

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Prasad Neerati ◽  
Harika Prathapagiri
Keyword(s):  
Neuropathic Pain ◽  
Peripheral Neuropathy ◽  
Sciatic Nerve ◽  
Lipoic Acid ◽  
Normal Saline ◽  
Chronic Constriction Injury ◽  
Thermal Hyperalgesia ◽  
Alpha Lipoic Acid ◽  
Chronic Neuropathic Pain ◽  
Neuropathic Pain Syndrome

Abstract Background Chronic neuropathic pain syndrome is associated with impaired quality of life and is poorly manageable. Alpha lipoic acid (ALA) is a powerful antioxidant and showed its effectiveness on diabetic neuropathy and other acute peripheral nerve injuries but it was not evaluated in the chronic neuropathic pain, chronic constriction injury (CCI) in rat model by using duloxetine (DLX) as standard. Methodology The main objective of the study was to expedite ALA effect on chronic peripheral neuropathy induced by CCI of sciatic nerve in rats. In this study, male Wister rats were randomly divided into six groups (n = 8) including, normal saline, sham operated, surgery control, DLX 30mg/kg treated, ALA treated 25mg/kg, and ALA+DLX. The CCI of sciatic nerve was conducted on all animals except normal saline group and studied for 21 days (i.e. 14 days treatment period & 7 days treatment free period) by using different behavioral, biochemical and, histopathology studies. Results ALA showed minor but significant decrease of thermal hyperalgesia, cold allodynia, malondialdehyde (MDA), total protein, lipid peroxidation, and nitric oxide levels and significant increase of motor coordination, glutathione level and decreased axonal degeneration significantly. These effects sustained even during treatment free period. ALA enhanced the effect of DLX when given in combination by showing sustained effect. In conclusion, ALA acted as potent antioxidant may be this activity is responsible for the potent neuroprotective effect. Conclusion Hence, ALA attenuated the nueroinflammation mediated by chronic peripheral neuropathy. Further studies are warranted with ALA to develop as a clinically relevant therapeutic agent for the treatment of neuropathic pain.

Whole‐body reversible neuropathic pain associated with right parieto‐temporal operculum single inflammatory lesion in a patient with multiple sclerosis: A case report

2019 ◽  
Vol 23 (10) ◽  
pp. 1763-1766 ◽  
Author(s):  
Louis Poncet‐Megemont ◽  
Radhouane Dallel ◽  
Carine Chassain ◽  
Antoine Perrey ◽  
Sophie Mathais ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Neuropathic Pain ◽  
Case Report ◽  
Inflammatory Lesion ◽  
Whole Body

scholarly journals Alpha‐lipoic acid downregulates TRPV1 receptor via NF‐κB and attenuates neuropathic pain in rats with diabetes

2020 ◽  
Vol 26 (7) ◽  
pp. 762-772 ◽  
Author(s):  
Bing‐Yu Zhang ◽  
Yi‐Lian Zhang ◽  
Qian Sun ◽  
Ping‐An Zhang ◽  
Xi‐Xi Wang ◽  
...  
Keyword(s):  
Neuropathic Pain ◽  
Lipoic Acid ◽  
Alpha Lipoic Acid ◽  
Trpv1 Receptor

A rare cause of status epilepticus; alpha lipoic acid intoxication, case report and review of the literature

2015 ◽  
Vol 19 (6) ◽  
pp. 730-732 ◽  
Author(s):  
Orkun Tolunay ◽  
Tamer Çelik ◽  
Mustafa Kömür ◽  
Ali Emre Gezgin ◽  
Musa Soner Kaya ◽  
...  
Keyword(s):  
Case Report ◽  
Status Epilepticus ◽  
Lipoic Acid ◽  
Alpha Lipoic Acid ◽  
Review Of The Literature

scholarly journals Effect of alpha-lipoic acid on asymmetric dimethylarginine and disability in multiple sclerosis patients: A randomized clinical trial

10.19082/4899 ◽  
2017 ◽  
Vol 9 (7) ◽  
pp. 4899-4905 ◽  
Author(s):  
Mohammad Khalili ◽  
Madjid Soltani ◽  
Shirin Amiri Moghadam ◽  
Parvin Dehghan ◽  
Amirreza Azimi ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Lipoic Acid ◽  
Asymmetric Dimethylarginine ◽  
Alpha Lipoic Acid ◽  
Multiple Sclerosis Patients

scholarly journals Verification of neuroprotective effects of alpha-lipoic acid on chronic neuropathic pain in a chronic constriction injury rat model

2021 ◽  
Vol 16 (1) ◽  
pp. 222-228
Author(s):  
Junhao Wang ◽  
Zhaohui Lou ◽  
Haiyang Xi ◽  
Zhi Li ◽  
Lepeng Li ◽  
...  
Keyword(s):  
Neuropathic Pain ◽  
Lipoic Acid ◽  
Rat Model ◽  
Chronic Constriction Injury ◽  
Neuroprotective Effect ◽  
Alpha Lipoic Acid ◽  
Chronic Neuropathic Pain ◽  
Neuroprotective Effects ◽  
Satellite Glial Cells ◽  
Withdrawal Threshold

Abstract Treatment of neuropathic pain is far from satisfactory. This study sought evidence of a neuroprotective effect of alpha-lipoic acid (ALA) to treat neuropathic pain in a chronic constriction injury (CCI) rat model. A total of 48 rats were randomly divided into sham, CCI, or CCI + ALA groups. Mechanical and thermal nociceptive thresholds were evaluated as behavioral assessments. Dorsal root ganglia cells were assessed morphologically with hematoxylin and eosin staining and for apoptosis with P53 immunohistochemical staining. Compared with the sham group, the CCI group had a shorter paw withdrawal threshold and paw withdrawal latency, abnormal morphologic manifestations, and increased numbers of satellite glial cells and P53+ cells. These changes were significantly reversed by treatment with ALA. Our study indicates neuroprotective effects of ALA on chronic neuropathic pain in a CCI rat model. ALA is potentially considered to be developed as a treatment for neuropathic pain caused by peripheral nerve injury, which requires further verification.

Sign in / Sign up

Export Citation Format

Share Document